Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.34 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL419801 | 1.00 | DPP4 (0.34) | DPP4MMECYP4F2CYP4A11 | |
| SCHEMBL420711 | 1.00 | DPP4 (0.34) | DPP4MMECYP4F2CYP4A11 | |
| SCHEMBL422018 | 0.97 | — | — | |
| SCHEMBL420704 | 0.92 | — | — | |
| Hydrochloric Acid SCHEMBL17443677 | 0.86 | — | — | |
| SCHEMBL420695 | 0.86 | — | — | |
| SCHEMBL28262535 | 0.80 | CYP4F2 (0.32) | CYP4F2CYP4A11 | |
| SCHEMBL817636 | 0.78 | SLC6A4 (0.30) | — | |
| SCHEMBL5703284 | 0.76 | — | — | |
| SCHEMBL5703325 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9879025-B2 | Transfer hydrogenation of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170029433-A1 | TRANSFER HYDROGENATION OF CYCLOPAMINE ANALOGS | ROYALTY SECURITY, LLC | 2017-02-02 | — | — | US | disclosed |
| US-9394313-B2 | Transfer hydrogenation of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-9376447-B2 | Transfer hydrogenation of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20120065400-A1 | Transfer Hydrogenation of Cyclopamine Analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065399-A1 | Transfer Hydrogenation of Cyclopamine Analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065400-A1 | Transfer Hydrogenation of Cyclopamine Analogs | HVCN1, KCNQ4, KCNQ5 | DPP4 1792/4885MME 4300/4885CYP4F2 213/4885 |
| US-20120065399-A1 | Transfer Hydrogenation of Cyclopamine Analogs | HVCN1, KCNQ4, KCNQ5 | DPP4 1792/4885MME 4300/4885CYP4F2 213/4885 |
| US-20170029433-A1 | TRANSFER HYDROGENATION OF CYCLOPAMINE ANALOGS | HVCN1, KCNQ4, KCNQ5 | DPP4 1792/4885MME 4300/4885CYP4F2 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.